Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 3
2008 6
2009 4
2010 1
2012 1
2013 3
2014 3
2016 1
2017 1
2020 3
2021 4
2022 1
2024 1
2025 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial.
Loges S, Heuser M, Chromik J, Sutamtewagul G, Kapp-Schwoerer S, Crugnola M, Di Renzo N, Lemoli R, Mattei D, Fiedler W, Alvarado-Valero Y, Ben-Batalla I, Waizenegger J, Rieckmann LM, Janning M, Collienne M, Imbusch CD, Beumer N, Micklem D, H Nilsson L, Madeleine N, McCracken N, Oliva C, Gorcea-Carson C, Gjertsen BT. Loges S, et al. Among authors: oliva c. Nat Commun. 2025 Mar 23;16(1):2846. doi: 10.1038/s41467-025-58179-6. Nat Commun. 2025. PMID: 40122885 Free PMC article. Clinical Trial.
Combinations take centre stage in PD1/PDL1 inhibitor clinical trials.
Upadhaya S, Neftelino ST, Hodge JP, Oliva C, Campbell JR, Yu JX. Upadhaya S, et al. Among authors: oliva c. Nat Rev Drug Discov. 2021 Mar;20(3):168-169. doi: 10.1038/d41573-020-00204-y. Nat Rev Drug Discov. 2021. PMID: 33177720 Review. No abstract available.
Trends in clinical development for PD-1/PD-L1 inhibitors.
Xin Yu J, Hodge JP, Oliva C, Neftelinov ST, Hubbard-Lucey VM, Tang J. Xin Yu J, et al. Among authors: oliva c. Nat Rev Drug Discov. 2020 Mar;19(3):163-164. doi: 10.1038/d41573-019-00182-w. Nat Rev Drug Discov. 2020. PMID: 32127660 No abstract available.
Impact of COVID-19 on oncology clinical trials.
Upadhaya S, Yu JX, Oliva C, Hooton M, Hodge J, Hubbard-Lucey VM. Upadhaya S, et al. Among authors: oliva c. Nat Rev Drug Discov. 2020 Jun;19(6):376-377. doi: 10.1038/d41573-020-00093-1. Nat Rev Drug Discov. 2020. PMID: 32424343 No abstract available.
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D. Geyer CE, et al. Among authors: oliva c. N Engl J Med. 2006 Dec 28;355(26):2733-43. doi: 10.1056/NEJMoa064320. N Engl J Med. 2006. PMID: 17192538 Free article. Clinical Trial.
Leishmania infantum EndoG is an endo/exo-nuclease essential for parasite survival.
Rico E, Oliva C, Gutierrez KJ, Alzate JF, Genes CM, Moreno D, Casanova E, Gigante A, Pérez-Pérez MJ, Camarasa MJ, Clos J, Gago F, Jiménez-Ruiz A. Rico E, et al. Among authors: oliva c. PLoS One. 2014 Feb 26;9(2):e89526. doi: 10.1371/journal.pone.0089526. eCollection 2014. PLoS One. 2014. PMID: 24651293 Free PMC article.
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M. Johnston S, et al. Among authors: oliva c. J Clin Oncol. 2009 Nov 20;27(33):5538-46. doi: 10.1200/JCO.2009.23.3734. Epub 2009 Sep 28. J Clin Oncol. 2009. PMID: 19786658 Clinical Trial.
32 results